Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 21, 2022
Deals
Oct. 21 Quick Takes: Newly spun out Biohaven prices upsized follow-on
Plus Singapore’s AUM merging with SPAC, and updates from Angelini and DeepUll
BioCentury | Aug 8, 2020
Translation in Brief
Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more
BioCentury’s roundup of preclinical news
BioCentury | Jan 9, 2020
Product Development
Pfizer dips into translational regulation for cancer with eFFECTOR deal
Pfizer’s deal with eFFECTOR points to translational regulators as an emerging target source
BioCentury | May 24, 2019
Emerging Company Profile
Anima opens new target space in translational control
How Anima is leveraging its translational control platform to pursue new targets, small molecules and big pharma deals
BioCentury | Feb 2, 2018
Clinical News
Effector reports Phase I/II data for eFT508 in hematological malignancies
BioCentury | Jul 29, 2017
Finance
Potentiator potential
Why Pfizer Venture Investments led Effector's $38.6M series C
Items per page:
1 - 10 of 12